Navigation Links
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Date:2/8/2013

enues under the Company's elagolix collaboration agreement. Revenues for the year ended December 31, 2012 were $53.1 million, compared with $77.4 million for 2011. The $24.3 million decrease in revenue is primarily due to $30 million in milestones achieved under the Company's elagolix collaboration agreement during the third quarter of 2011.

Research and development expenses increased to $9.1 million during the fourth quarter of 2012 compared with $8.0 million for the same period in 2011. For the year ended December 31, 2012, research and development expenses were $37.2 million, compared to $31.0 million for 2011. The increase in research and development expenses is primarily driven by Phase IIb development expenses for the VMAT2 program, coupled with increased compensation related costs, primarily due to equity based compensation.

General and administrative expenses increased to $3.3 million during the fourth quarter of 2012 compared with $2.7 million for the same period last year. For the year ended December 31, 2012, general and administrative expenses were $13.4 million, compared to $12.5 million for 2011. The increase in year-to-date general and administrative expenses is primarily related to higher equity based compensation costs.

2013 Financial GuidanceThe Company expects to have a net cash burn from operations of approximately $50 to $55 million in 2013. Revenue is expected to approximate $3 million which consists solely of the amortization of up-front license fees. Expenses for 2013 should approximate $55 to $60 million. Net loss for 2013 is expected to be $50 to $55 million, or $0.75 to $0.83 loss per share based on 66.5 million basic shares outstanding. The Company expects to end 2013 with in excess of $130 million in cash, investments and receivables.

Pipeline HighlightsElagolix UpdateAbbVie is currently conducting the initial Phase III study of elagolix for endometriosis, the Violet Petal Study. The study is a 24-week
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
2. Neurocrine Biosciences Reports Third Quarter 2012 Results
3. Neurocrine Biosciences Reports Second Quarter 2012 Results
4. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
5. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
6. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
7. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
8. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
9. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
10. Pressure BioSciences, Inc. Appoints Conrad F. Mir as Chief Financial Officer
11. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Revolutionary Science, the manufacturer of the ... that they have expanded their colony counter product line ... InCount and ImpressCount. These affordable colony counters that ... food microbiology and pharmaceutical manufacturing. , The previously released ... bright white enclosure with jet black accents represent the ...
(Date:5/21/2013)... 21, 2013 Vital Imaging ™ ... of California, San Diego for a joint study which ... MRI (Magnetic Resonance Imaging) with that of a supine ... continued pursuit of improved healthcare by combining cutting edge ... an extremely valuable tool for evaluating pathological changes in ...
(Date:5/21/2013)... 2013 PathoGenetix, Inc., a commercial-stage developer ... announced today that it has successfully identified and strain ... obtained from the Centers for Disease Control and Prevention ... The findings are detailed in a poster ... for Microbiology in Denver on Monday. , The 250 ...
(Date:5/20/2013)... MELBOURNE, Australia , May 20, 2013 ... of Agriculture,s (USDA) Agricultural Research Service (ARS) in ... market opportunity , Trials to begin ... Australian drug delivery technology company Phosphagenics Limited ... U.S. Department of Agriculture,s (USDA) Agricultural Research Service (ARS) ...
Breaking Biology Technology:Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Vital Imaging Makes Greater Commitment into MRI Research 2Vital Imaging Makes Greater Commitment into MRI Research 3New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3Phosphagenics Signs Research Agreement with the Agricultural Research Service 2
... (OTC Bulletin Board: ARNI), today announced that its ... changed from "LRRI.OB" to "ARNI.OB",effective July 17, 2008., ... is a clinical-stage biopharmaceutical company,that develops and commercializes ... lead compound is AR-67, a novel, third-generation,camptothecin analogue ...
... TOKYO, and NEW DELHI, India, July 17 ... media and the stock market, Daiichi Sankyo,Company, ... Laboratories,Limited (NSE/BSE: Ranbaxy/500359) ("Ranbaxy") reiterate that the ... family, the largest,controlling shareholders of Ranbaxy, is ...
... Supply Solutions(R),a focus area within SAFC(R), a ... today that the Company has launched a ... with their regulatory,requirement under the new European ... Authorization and restriction of Chemicals,(REACH) http://www.safcsupplysolutions.com/reach ...
Cached Biology Technology:Arno Therapeutics Announces New Ticker Symbol 2Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 2SAFC Supply Solutions Launches REACH-Compliant Products and Support 3
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
(Date:5/17/2013)... China---- Why Tibetan antelope can live at elevations ... collaborative research published in Nature Communications , ... provide evidence that some genetic factors may be ... environments. The data in this work will also ... the biology of other ruminant species. , The ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4The genome sequence of Tibetan antelope sheds new light on high-altitude adaptation 2
... smallest possible scales using molecules and individual atoms ... challenging. An interdisciplinary team of researchers at the University ... selecting the best of these blocks, drawing inspiration from ... The team was led by postdoctoral fellow Gevorg ...
... Institute scientists has found a key biological mechanism underpinning ... door to the development of drugs to manage excessive ... much of our lab,s research, was to examine the ... drinking driven by the aversive aspects of alcohol withdrawal," ...
... Bethesda, MDIf you are one of the millions of ... good news is on the way. A new research discovery ... https://www.jleukbio.org ) offers hope for new drugs that treat the ... because the research is the first to identify natural killer ...
Cached Biology News:Penn researchers help nanoscale engineers choose self-assembling proteins 2Penn researchers help nanoscale engineers choose self-assembling proteins 3Scripps Research scientists find key mechanism in transition to alcohol dependence 2Scripps Research scientists find key mechanism in transition to alcohol dependence 3Harvard scientists 'see' the early cellular cause of dry eye disease for the first time 2
Rabbit polyclonal to Myosin VIIa (rating: *****) ( Abpromise for all tested applications). entrezGeneID: 4647 SwissProtID: Q13402...
Rabbit polyclonal to GPCR G2A ( Abpromise for all tested applications). entrezGeneID: 29933 SwissProtID: Q9UNW8...
6-keto Prostaglandin F1α EIA Antiserum 6-keto-PGF1alpha EIAs prostaglandins antisera enzyme immunoassays reagents 6-keto-PGF1.alpha....
...
Biology Products: